14 completed, 4 recruiting, 1 active not recruiting. 19 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 14, Recruiting 4, Active not recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Zealand Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes Petrelintide, Placebo - Obesity or Overweight, Type 2 Diabetes | Phase 3 | Recruiting | Hoffmann-La Roche | 600 | 2026-10-09 | 2026-11-05 |
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease Petrelintide, Placebo - Obesity or Overweight, Cardiovascular Disease | Phase 3 | Recruiting | Hoffmann-La Roche | 2500 | 2026-09-30 | 2026-10-07 |
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity Petrelintide, Placebo - Obesity or Overweight | Phase 3 | Recruiting | Hoffmann-La Roche | 3900 | 2026-09-30 | 2026-11-05 |
| Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS Glepaglutide, Placebo - Short Bowel Syndrome | Phase 3 | Recruiting | Zealand Pharma | 90 | 2026-02-11 | 2026-09-29 |
| Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome Glepaglutide 10 mg - Short Bowel Syndrome (SBS) | Phase 3 | Active not recruiting | Zealand Pharma | 28 | 2025-12-11 | 2026-07-30 |
| A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D Dasiglucagon - Hypoglycemia, Type 1 Diabetes | Phase 3 | Completed | Zealand Pharma | 8 | 2023-05-09 | 2025-07-20 |
| The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome Glepaglutide - Short Bowel Syndrome | Phase 3 | Completed | Zealand Pharma | 12 | 2021-08-10 | 2024-11-22 |
| Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial Glepaglutide - Short Bowel Syndrome | Phase 3 | Completed | Zealand Pharma | 84 | 2021-06-16 | 2026-09-08 |
| Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism dasiglucagon, Placebo - Congenital Hyperinsulinism | Phase 2 / Phase 3 | Completed | Zealand Pharma | 12 | 2020-06-19 | 2025-03-14 |
| The Bihormonal iLet Bionic Pancreas Feasibility Study Bihormonal iLet Bionic Pancreas, Insulin-only Bionic Pancreas, Dasiglucagon - Type 1 Diabetes Mellitus | Phase 2 / Phase 3 | Completed | Massachusetts General Hospital | 12 | 2019-05-15 | 2019-12-16 |
| Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS glepaglutide - Short Bowel Syndrome | Phase 3 | Completed | Zealand Pharma | 150 | 2019-05-07 | 2026-09-08 |
| Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism dasiglucagon - Congenital Hyperinsulinism | Phase 3 | Completed | Zealand Pharma | 42 | 2019-05-02 | 2026-08-03 |
| A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM dasiglucagon - Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | Completed | Zealand Pharma | 92 | 2019-03-26 | 2023-02-21 |
| A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism Dasiglucagon, Standard of Care - Congenital Hyperinsulinism | Phase 3 | Completed | Zealand Pharma | 32 | 2019-02-07 | 2023-12-13 |
| Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM Dasiglucagon, Placebo - Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | Completed | Zealand Pharma | 45 | 2018-11-01 | 2021-05-19 |
| Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS) glepaglutide, Placebo - Short Bowel Syndrome | Phase 3 | Completed | Zealand Pharma | 106 | 2018-10-04 | 2025-07-17 |
| Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children dasiglucagon, placebo, GlucaGen HypoKit - Hypoglycemia | Phase 3 | Completed | Zealand Pharma | 42 | 2018-09-28 | 2021-06-30 |
| A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects Dasiglucagon, GlucaGen, Placebo - Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | Completed | Zealand Pharma | 170 | 2017-12-07 | 2021-06-10 |
| A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus dasiglucagon, GlucaGen - Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | Completed | Zealand Pharma | 112 | 2017-06-28 | 2021-05-04 |
Diabetes Mellitus, Type 1 (6) · Hypoglycemia (6) · Short Bowel Syndrome (6) · Congenital Hyperinsulinism (3) · Obesity (3) · Overweight (3) · Digestive System Diseases (2) · Gastrointestinal Diseases (2) · Intestinal Diseases (2) · Malabsorption Syndromes (2) · Pathologic Processes (2) · Postoperative Complications (2) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1)
dasiglucagon (10) · Glucagon-Like Peptide 1 (2) · Standard of Care (1)
United States (17) · Germany (11) · United Kingdom (7) · Canada (6) · Belgium (5) · Denmark (5) · France (5) · Poland (5) · Netherlands (4) · Austria (3) · Israel (3) · Finland (1) · Hungary (1) · Italy (1) · Norway (1)
Christina M Sylvest, MSc Pharm (2) · Christina Sylvest, MSc Pharm (2) · Charlotte Teglman Schioeler (1) · Jelena Ivkovic, MD (1) · Steven J Russell, MD, PhD (1) · Stine J Maarbjerg, PHD (1)
PMID 33906916, PMID 35239971, PMID 39708985
2017 (1), 2025 (1)